Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy.
An increased incidence of complications of atherosclerosis has been noted in cancer survivors. The aim of the present study was to evaluate, in patients with breast carcinoma, the effect of antracycline-based chemotherapy on carotid intima-media thickness (IMT), myocardial perfusion, assessed by single-photon emission tomography (SPECT) and laboratory parameters associated with the risk of atherosclerosis. Thirty-six patients with breast cancer were evaluated before and after anthracycline-based chemotherapy. Retinol, alpha-tocopherol, glycosylated hemoglobin and urinary neopterin were measured by high-performance liquid chromatography. Peripheral blood cell count, D-dimers, fibrinogen, antithrombin, glucose, magnesium, creatinine, uric acid, albumin, C-reactive protein, lipoprotein (a), cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, homocysteine, urinary albumin and N-acetyl-beta-D-glucosaminidase (NAG) were determined with routine methods. No significant differences were observed between patients and 16 controls. Compared to the measurement before the start of therapy, peripheral blood leukocyte and platelet count, hemoglobin, creatinine, HDL cholesterol, retinol, albumin, urinary albumin and NAG decreased, and total cholesterol, LDL cholesterol, triglycerides, neopterin and mean IMT increased significantly after the treatment. Of the 36 patients who had SPECT after treatment, perfusion defects were noted only in two cases, including the patient who had perfusion defects at baseline examination and a patient who did not have a baseline SPECT. In conclusion, a significant increase in carotid IMT, total cholesterol, LDL cholesterol, triglycerides and urinary neopterin and a decrease of peripheral blood leukocyte and platelet counts, hemoglobin, creatinine, HDL cholesterol, retinol, albumin and NAG were observed after the treatment.
Kalábová
Hana
H
Department of Oncology and Radiotherapy, Charles University School of Medicine, Hradec Kralove, Czech Republic.
Melichar
Bohuslav
B
Ungermann
Leoš
L
Doležal
Jiří
J
Krčmová
Lenka
L
Kašparová
Markéta
M
Plíšek
Jiří
J
Hyšpler
Radomír
R
Pecka
Miroslav
M
Solichová
Dagmar
D
D000328:Adult; D018943:Anthracyclines / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D050197:Atherosclerosis / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D002277:Carcinoma / Q000150:complications* / Q000188:drug therapy*; D059168:Carotid Intima-Media Thickness; D005260:Female; D006801:Humans; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D012307:Risk Factors; D015899:Tomography, Emission-Computed, Single-Photon; D017539:Tunica Intima / Q000473:pathology; D017540:Tunica Media / Q000473:pathology
D018943:Anthracyclines